Enfusion, Inc. (NYSE:ENFN) Insider Bronwen Bastone Sells 3,126 Shares

Enfusion, Inc. (NYSE:ENFN) insider Bronwen Bastone sold 3,126 shares of Enfusion stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $11.38, for a total transaction of $35,573.88. Following the sale, the insider now directly owns 221,875 shares of the company’s stock, valued at $2,524,937.50. This represents a 1.39 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Bronwen Bastone also recently made the following trade(s):

• On Monday, March 3rd, Bronwen Bastone sold 2,064 shares of Enfusion stock. The stock was sold at an average price of $11.48, for a total transaction of $23,694.72.
• On Tuesday, January 7th, Bronwen Bastone sold 809 shares of Enfusion stock. The stock was sold at an average price of $10.13, for a total transaction of $8,195.17.

Enfusion Trading Down 0.5 %

Shares of ENFN stock traded down $0.06 during mid-day trading on Friday, reaching $11.24. The stock had a trading volume of 970,369 shares, compared to its average volume of 1,164,913. The stock’s 50-day moving average price is $10.98 and its two-hundred day moving average price is $9.88. Enfusion, Inc. has a 52-week low of $7.83 and a 52-week high of $11.80. The firm has a market capitalization of $1.44 billion, a PE ratio of 280.95, a price-to-earnings-growth ratio of 1.85 and a beta of 0.95.

Enfusion (NYSE:ENFN) last released its quarterly earnings data on Monday, March 3rd. The company reported $0.01 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). Enfusion had a net margin of 1.70% and a return on equity of 6.67%. The firm had revenue of $52.94 million during the quarter, compared to analysts’ expectations of $53.98 million. On average, equities research analysts forecast that Enfusion, Inc. will post 0.06 earnings per share for the current year.

Hedge Funds Weigh In On Enfusion

A number of hedge funds have recently modified their holdings of the company. Centiva Capital LP increased its position in shares of Enfusion by 5.0% in the third quarter. Centiva Capital LP now owns 25,596 shares of the company’s stock valued at $243,000 after acquiring an additional 1,227 shares during the period. Harbor Capital Advisors Inc. increased its position in shares of Enfusion by 12.4% during the third quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock valued at $113,000 after buying an additional 1,315 shares during the period. Mackenzie Financial Corp increased its position in shares of Enfusion by 4.8% during the fourth quarter. Mackenzie Financial Corp now owns 31,271 shares of the company’s stock valued at $322,000 after buying an additional 1,434 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Enfusion by 5.9% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,070 shares of the company’s stock valued at $289,000 after buying an additional 1,567 shares during the period. Finally, Rhumbline Advisers increased its position in shares of Enfusion by 3.0% during the fourth quarter. Rhumbline Advisers now owns 62,464 shares of the company’s stock valued at $643,000 after buying an additional 1,796 shares during the period. Hedge funds and other institutional investors own 81.05% of the company’s stock.

Analysts Set New Price Targets

ENFN has been the topic of a number of analyst reports. Piper Sandler lifted their target price on shares of Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a research report on Monday, December 23rd. Stifel Nicolaus lifted their target price on shares of Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. Finally, William Blair reiterated a “market perform” rating on shares of Enfusion in a research report on Monday, January 13th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $11.13.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.